Fate Therapeutics Inc [FATE] stock is trading at $1.19, up 13.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FATE shares have gain 13.33% over the last week, with a monthly amount glided 9.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on October 31, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Wedbush upgraded its rating to Outperform on October 27, 2025, and kept the price target unchanged to $7. On November 18, 2024, upgrade upgraded it’s rating to Neutral. Piper Sandler upgraded its rating to an Overweight and increased its price target to $6 on June 17, 2024. H.C. Wainwright downgraded its rating to Neutral for this stock on January 24, 2023, and downed its price target to $7. In a note dated January 06, 2023, Wedbush downgraded a Neutral rating on this stock and revised its target price from $42 to $7.
Fate Therapeutics Inc [FATE] stock has fluctuated between $0.66 and $1.94 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $1.19 at the most recent close of the market. An investor can expect a potential return of 3219.33% based on the average FATE price forecast.
Analyzing the FATE fundamentals
Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 7.14M for the trailing twelve months, which represents a drop of -43.36%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -24.48%, Pretax Profit Margin comes in at -21.87%, and Net Profit Margin reading is -21.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.57 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Fate Therapeutics Inc’s Current Ratio is 7.87. As well, the Quick Ratio is 7.87, while the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 19.23, the price to book ratio is 0.59.
Transactions by insiders
Recent insider trading involved TAHL CINDY, that happened on Jan 09 ’26 when 10589.0 shares were sold. President and CEO, Valamehr Bahram completed a deal on Jan 09 ’26 to sell 5190.0 shares. Meanwhile, Officer TAHL CINDY bought 10589.0 shares on Jan 09 ’26.
